celgene

Bristol-Myers-Squibb announced that Amgen will acquire Celgene’s Otezla business for $13.4 billion in a cash transaction. Bristol-Myers now expects to complete the pending merger with Celgene by the end of 2019. For More:

Celgene Corp. (CELG) swung to a profit in the fourth quarter from a loss last year, helped by lower research and development costs as well as a decline in acquisition-related charges and restructuring. A drop in income tax provision also contributed to the bottom line growth. The results...

Bristol-Myers Squibb acquires Celgene for $74 billion. Celgene stock surges while BMY plunges. 2019 starts well for Celgene. More M&As are in the pipeline in the biopharma space.

What's the reason for Celgene going down even after beating the estimates and lifting 2018 outlook? Any thoughts? https://news.alphastreet.com/celgene-celg-stock-q3-2018-earnings/

Celgene's second quarter results beat estimates and the company lifted 2018 outlook. Celgene will not be increasing the price of its products this year. https://news.alphastreet.com/celgene-q2-2018-earnings/

In the past two weeks, Celgene has reported positive results from 3 clinical trials. This includes two studies with its partner Acceleron. https://news.alphastreet.com/celgene-gets-a-booster-shot-from-recent-positive-clinical-trial-results/

Just days after FDA announced a list of companies that use “gaming” tactics to delay the entry of the generic competitors, Celgene plunges to a new 52-week low. Celgene topped FDA’s list with 31 complaints. https://news.alphastreet.com/celgene-plunges-to-a-new-52-week-low-battered-by-setbacks/

Celgene reported better-than-expected first quarter results, as its flagship drug for multiple myeloma continued to increase in new and repeat prescriptions and longer average duration of use. Revenue continued to be benefited from the company’s key growth driver Revlimid, which was approved...

From 1-10

Gilead Sciences (GILD) reported a 43% dip in earnings for the first quarter due to lower product sales and prescription trends. Higher competition and lower sales of certain hepatitis C products too impacted sales during the quarter. Infographics of the results. The market has huge hopes for...

It’s no big secret that investment in biotech stocks can offer great returns for investors, and at the same time, they can do some serious damage also. Some of these companies not just tackle serious issues like cancer, but also prove to be a life-saving medicine in an investor’s portfolio...

https://news.alphastreet.com/celgenes-potential-blockbuster-drug-filing-fails-to-pass-the-muster-with-the-fda/ “Refuse to file” letter sent to Celgene by FDA for the NDA filed for Ozanimod drug for treating patients with relapsed multiple sclerosis

http://alph.st/ba1df6ff Higher sales of Revlimid and Otezla help Celgene to report better than expected sales figure. Will the two (Impact and Juno) multi-billion dollar acquisitions help the struggling Celgene in 2018 and beyond?

It's an M&A Monday for the pharma companies. Two major pharma acquisitions announced today. 1) Celgene acquires Juno for $9 billion http://alph.st/pd7bf702 2) Sanofi acquires Bioverative for $11.6 billion Last week, there was a rumor that Celgene's acquisition of Juno and also news about...

Yesterday, WSJ has stated that Celgene is holding talks to acquire Juno Therapeutics. http://alph.st/pd7bf702 Will this move strengthen Celgene? In 2018, the first acquisition was Impact and now the unconfirmed Juno hunting.

Celgene strengthens its cancer portfolio by acquiring Impact Biomedicines. After stopping the Crohn's disease treatment trials and cutting down the 2020 outlook recently, this deal is a positive news for Celgene. But Sanofi had sold the rights of fedrantinib to Impact in 2016 when the drug was...

A trial testing Revlimid on follicular lymphoma did not meet the desired endpoint. Biogen's RITUXAN also fails..

Celgene announces positive results from the trials with its development partners Bluebird Bio and Juno Therapeutics in ASH 2017. I think it's an advantage for all the three companies involved; especially for Bluebird Bio.

http://alph.st/b9f74234 Remember, Celgene settled a lawsuit for the fraudulent use of Thalomid in July 2017 for $280 million. Now Lannett is going to manufacture the generic version of Thalomid.

http://alphastreet.com/b0662389 Celgene's outlook, especially it's long-term targets, is not an encouraging one. Also, a decrease in pharma company's research and development expenses is not a good sign.